Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupLeukocyte diseasesDiseaseHypereosinophilic SyndromeSubgroupICD10D47.5MeSHHypereosinophilic SyndromeSequenceChemotherapyChemo-substanceMepolizumabChemo-substanceMepolizumabChemo-substanceMepolizumabChemo-substanceMepolizumabNo. Substances1 RadiotherapySupportive therapySupportive substanceBenralizumabSupportive substanceBenralizumabSupportive substanceBenralizumabSupportive substanceBenralizumabNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationSecond lineseveral possibleTherapy phaseTherapy intentiondisease controlRisksDiarrheaEmetogenicity (ASCO)HeadacheInfusion ReactionPruritusUpper Respiratory Tract Infection only studiesPublicationAuthorOgbogu PU Roufosse FDiseaseFIP1L1-PDGFRA–negative HESFIP1L1-PDGFRA–negative HES oder unkontrolliertes HES, ZweitlinieOriginBrussels, Belgium, HES Mepolizumab study groupUniversity Hospitals Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USAProtokolle in Überarbeitung 2 protocols foundBenralizumab 30, hypereosinophilic syndrome (PID3255 V1.0)Mepolizumab 300, hypereosinophilic syndrome (PID2092 V1.0)
